Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

Literature DB >> 21422405

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

Daniel B Costa¹, Susumu Kobayashi, Shuchi S Pandya, Wee-Lee Yeo, Zhongzhou Shen, Weiwei Tan, Keith D Wilner.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2011 PMID： 21422405 DOI： 10.1200/JCO.2010.34.1313

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

Keyword Cloud
Cited

× No keyword cloud information.

215 in total

1. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors: Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal: J Natl Compr Canc Netw Date: 2014-11 Impact factor: 11.908

Review 2. New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.

Authors: Laird Cameron; Benjamin Solomon
Journal: Curr Treat Options Oncol Date: 2015-10

3. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.

Authors: D Ross Camidge; Margaret Skokan; Porntip Kiatsimkul; Barbara Helfrich; Xian Lu; Anna E Barón; Nathan Schulte; DeLee Maxson; Dara L Aisner; Wilbur A Franklin; Robert C Doebele; Marileila Varella-Garcia
Journal: Cancer Date: 2013-09-10 Impact factor: 6.860

Review 4. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.

Authors: James E Frampton
Journal: Drugs Date: 2013-12 Impact factor: 9.546

5. Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.

Authors: Yuan-Yuan Lei; Jin-Ji Yang; Wen-Zhao Zhong; Hua-Jun Chen; Hong-Hong Yan; Jie-Fei Han; Lu-Lu Yang; Yi-Long Wu
Journal: J Thorac Dis Date: 2015-07 Impact factor: 2.895

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

1. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Review 2. New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.

3. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.

Review 4. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.

5. Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.

Review 6. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

7. An orthotopic glioblastoma animal model suitable for high-throughput screenings.

8. Managing treatment-related adverse events associated with Alk inhibitors.

Review 9. Systemic therapy of brain metastases.

Review 10. Crizotinib resistance: implications for therapeutic strategies.